“Getting stuck with LAM”: patients perspectives on living with Lymphangioleiomyomatosis by Amanda Belkin et al.
Belkin et al. Health and Quality of Life Outcomes 2014, 12:79
http://www.hqlo.com/content/12/1/79RESEARCH Open Access“Getting stuck with LAM”: patients perspectives
on living with Lymphangioleiomyomatosis
Amanda Belkin1, Karen Albright2,3, Kaitlin Fier1,3, Jennifer Desserich1 and Jeffrey J Swigris1*Abstract
Background: Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that affects almost exclusively
women and is most often diagnosed before menopause. The main symptom of LAM is shortness of breath. LAM
patients’ perceptions of how the disease impacts their lives is largely unknown, but such information could be
useful to generate patient reported outcome measures for use in drug trials (or other research studies) and to
formulate interventions aimed at easing the burdens LAM imposes on patients.
Objective: To capture patients’ perceptions of how LAM affects their lives.
Methods: We used reflexive team analysis to analyze transcripts from semi-structured focus groups conducted with
LAM patients at LAMposium 2013. We sought to determine what patients perceive as the primary symptoms of
LAM and how the disease affects them in their daily lives.
Results: The 37 participants described seven primary symptoms of LAM and five common psychological
experiences from living with the disease. Shortness of breath and low energy (or fatigue) dominated the
symptomatic picture; cough, sensations in the chest, difficulty sleeping, gastrointestinal issues, and mild cognitive
difficulties were less common. The common psychological experiences participants reported included frustration,
worry, loss of identity, embarrassment, and in some participants, a healthy defiance against the disease.
Conclusions: Patients perceive the physical symptoms from LAM to be intrusive and limiting. Women living with
LAM are frustrated by their physical limitations, and they worry about what the future will be like if the disease
progresses. Therapeutic interventions should take aim at improving these perceptions.Introduction
Lymphangioleiomyomatosis (LAM) is a rare, progressive
and incurable lung disease, diagnosed predominantly in
women of child-bearing age [1-3]. LAM occurs sporadic-
ally (S-LAM) or as a pulmonary manifestation of tuberous
sclerosis complex (TSC-LAM) [4]. In either case, abnor-
mal, smooth muscle-like cells (LAM cells), of unknown
origin, infiltrate the lung and cause the formation of
innumerable, thin-walled cysts. As functional lung paren-
chyma is replaced by space-occupying, air-filled cysts, pa-
tients become increasingly short of breath—in most cases,
hypoxemia develops within ten years of symptom onset
[3,5,6]. The predominant symptom of LAM is exertional
dyspnea; cough is variably present; and pneumothorax
may occur either as the initial manifestation, leading* Correspondence: swigrisj@njc.org
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unless otherwise stated.women to seek medical attention, or at other times
throughout the course of the disease [7].
In a recent trial, sirolimus was found to halt LAM pro-
gression, offering women with LAM a viable treatment op-
tion and, for the first time, hope against the ravages of the
disease [8]. Unfortunately, use of sirolimus is not without
problems. It is not uniformly effective, is not tolerated by
all women with LAM, and does not cure the disease. Fur-
ther, it possesses a number of potential side-effects, requires
routine blood monitoring, and questions remain about
when to initiate therapy with sirolimus. Thus, despite the
hope that sirolimus has brought to the entire LAM com-
munity, many women with LAM will continue to see their
conditions worsen, may require lung transplantation and,
ultimately, may die from disease progression.
Based on existing questionnaires, relative to the general
population, women with LAM have impaired quality of
life, particularly in domains that assess physical function-
ing [7]. However, to our knowledge, a qualitative studytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline characteristics of 37 focus group
participants with LAM














LAM duration in years 7.0 (1st quartile - 3rd quartile 2.2-15.2;
range 0.4-39.0) N = 33
FEV1% 66 (1st quartile - 3rd quartile 39–74;
range 2–99) N = 30
Using supplemental oxygen 16 (55%) N = 29










*N = 35; **N = 34; Values are counts (%) or median (1st quartile - 3rd quartile;
range).
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how LAM affects their lives, has never been conducted.
This leaves a large gap in our understanding of the true
impact of LAM on the individuals with this disease. We
conducted this qualitative study to capture and carefully
examine LAM patients’ perceptions of the burdens of this
disease and to gain a clearer understanding of how the
disease affects them in their daily lives.
Methods
We used convenience sampling to recruit participants
from the LAMposium meeting in Cincinnati, Ohio in
April 2013. At that meeting, we conducted seven semi-
structured focus groups (FGs) with LAM patients to in-
vestigate participants’ experiences with symptoms and the
effect of LAM on daily life. One FG was conducted with
TSC-LAM patients, and six FGs were with S-LAM pa-
tients. Each FG lasted approximately 1.5 hours, was con-
ducted in English by a member of the study team (A.B. or
J.S.) trained in qualitative data collection, and was digitally
recorded and then transcribed verbatim. The study was
approved by the Institutional Review Board at National
Jewish Health in Denver, Colorado (HS-2774); written in-
formed consent was provided by all participants.
FG data were analyzed in an iterative process involving
established qualitative content methods and reflexive team
analysis [9-11]. The qualitative data software program
ATLAS.ti v.7.0 (Scientific Software Development, GmbH,
Berlin) was used for data management and analysis. FG
transcripts were read multiple times to achieve immersion,
and code categories were then developed using an emer-
gent rather than a priori approach [11]. Members of the
study team applied the resulting codes to the transcripts,
meeting regularly to check new findings, discuss emergent
new codes and themes, and assess the preliminary results
of the analysis process [12,13].
Results
Thirty-seven women each participated in one FG (n = 5 for
the TSC-LAM FG and n = 5, 5, 6, 6, 5, and 5 for the six
S-LAM FGs). Participants’ baseline characteristics are dis-
played in Table 1. Seven primary symptoms and five com-
mon psychological experiences were emergent in the data.
Participants identified shortness of breath, low energy,
cough, sensations in the chest, difficulty sleeping, gastro-
intestinal issues, and mild cognitive difficulties as the pri-
mary physical symptoms of LAM, while frustration, worry,
loss of identity, embarrassment, and defiance were identi-
fied as the common psychological experiences (Table 2).
Symptoms
Shortness of breath and low energy were ubiquitous
among participants; roughly half of the sample described
one or the other as the predominant symptom of LAM.Participants described shortness of breath with various
activities, including showering, washing their hair, walk-
ing on level surfaces, walking while carrying even rela-
tively light loads, walking up inclines, and climbing
stairs. Walking and talking simultaneously was not pos-
sible for many women, because they would become
profoundly short of breath. Some recognized increased
shortness of breath after eating. As one participant said,
“Little by little there is less I can do comfortably [with-
out getting short of breath]”. Because of shortness of
breath, participants often found themselves “strategizing
every task”, going through mental calculations to deter-
mine whether they had the breath or energy to complete
them. Tasks or committed daily living activities (e.g.,
housework) were done “in spurts” and with advanced
planning and preparation. One participant described
putting items “at the bottom of the stairs to take upstairs
[in] one trip instead of three or five that you used to
Table 2 Disease-related topics mentioned by focus group
participants
Topic Number of the seven focus groups
in which the topic was mentioned
Symptoms
Shortness of breath 7
Low energy 7
Cough 7
Sensations in the chest 5
Difficulty sleeping 6
Gastrointestinal issues 4




Loss of identity 7
Embarrassment 6
Defiance 5
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selves throughout the day; however, many were also
frustrated that their slower pace prevented them from
“getting as much done” as they had in their “pre-LAM
days”. Participants also reported that shortness of breath
seemed to vary with weather patterns, becoming more se-
vere and limiting on days with extremes in temperature
(high or low), high humidity, or strong wind.
Low energy was referred to in various terms, including
“tiredness”, “extreme exhaustion”, “absolutely crushing
fatigue” and feeling “wiped”. Although participants tried
to “[make] sure [they] have the energy for all of the
needs [of the household]”, some described feeling such
profound fatigue that they could not meet those needs.
In the words of one woman, “forget dinner for the family.
I’m done”. Not only was low energy itself an impediment
to accomplishing daily tasks, attempts to overcome it were
frustratingly time-consuming. One participant noted that
“it seems to take up a lot of time just to rest”. Under-
standably, low energy even affected self-image. As one
participant put it, “I don’t like being tired. I like who I
used to be”.
Although less commonly mentioned than shortness of
breath and low energy, cough was present in many par-
ticipants. Most indicated that coughing was worse in the
morning and frequently occurred when talking. Wheez-
ing was variably present, but not described as particu-
larly prominent or bothersome. Many participants had
had one or more episodes of pneumothorax (PTx)
throughout the course of their illness. However, at ran-
dom times, when PTx was determined not to be the
cause, these women—as well as many women who had
never had a PTx—would experience a nagging heavinessor aching in the chest, sometimes described as a “twinge”
in the lungs. Several participants reported the ability to
sense and even predict barometric pressure changes based
on how their chest felt.
Poor sleep quality, abdominal bloating, and difficulty
thinking were also described by some participants. Most
desired to sleep more than they were able to. Many also
commonly experienced occasional episodes of waking up
with a start, feeling like they “forgot to breathe”. Some
participants described abdominal distension, bloating and
the inability to eat as much as they once did. About the
bloating, one participant stated, “…by the end of the day,
I’d look like I was three months pregnant”. Finally, some
participants also reported mild cognitive difficulties,
described variably as “brain fog” or in the context of
specific activities, such as “missing words while reading
or writing”.
Psychological experiences
A quote stated by different women in two separate FGs
was a thread that wove its way throughout all FGs and
encapsulated the psychological experience of living with
this disease was “getting stuck with LAM”. For some,
“getting stuck is, I think, emotionally with LAM”—not
being able to move past the fact that they had been diag-
nosed with a progressive, incurable disease. For other
women, “getting stuck” conveyed their feelings of having
been dealt a bad hand.
In the paragraphs that follow, we flesh out the five main
psychological themes that emerged, including frustration
and resentment, worry and fear, loss of identity, embar-
rassment and guilt, and finally defiance and resilience.
Frustration and resentment
Participants were clearly frustrated by the burdens LAM
placed on their lives and the way the disease seemed to
make them “…feel like your life is just totally ripped out
from under you”. Participants resented how indiscrimin-
ately LAM “[took] a lot of experiences from my life”, as
one young participant tearfully stated. They resented the
intrusion on their ability to live as carefree as they would
like, as one participant expressed, “I am a very spontan-
eous person, and I cannot stand how I have to con-
stantly make these stupid adjustments…and as I get
sicker, I’m going to have to make more of them”.
Women sensed living with a “pressure to keep up” that
was, for many, difficult to deal with: “I feel like I’m on
edge all the time. And I just wish I would be allowed to
do things at my own pace”.
Many participants’ frustration and resentment left them
wondering what they did to deserve LAM; as one partici-
pant questioned, “I’ve been a good girl…done what I should
do…so, now why am I not able to breathe? I’ve taken care
of myself, what’s the deal?” LAM’s omnipresence was
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day I don’t think about it [having LAM] just once during
the day”.
Worry and fear
There was worry about “…what is in store for me in the
future… [if LAM progresses and symptoms worsen]”.
Many women were trying to manage a household, to be
a mother to small children and/or work outside the
home, while living with the specter of LAM—and the
“…fear that there is something that is going to happen
that I can’t manage…” or wondering “what kind of burden
I’m going to put on my family [as she ages and LAM pro-
gresses]”. Many participants lived with the constant worry
that any fleeting sensation could be due to LAM and a
harbinger of disease progression. Like other patients with
chronic respiratory illness, for participants not using sup-
plemental oxygen, the threat of needing it loomed fore-
bodingly (Question: Do you have fears? “Yeah…being
tethered to oxygen all the time [laughing]…more so than
death [laughing].”).
Loss of identity
Some participants perceived that LAM had taken away
their identity (as a worker, an efficacious person, a pro-
ductive member of society, etc.)—as one woman said
“[LAM is] making of my life small, because of the tired-
ness”. Some women felt like they had lost their inde-
pendence, including one who said, “I have to rely on my
husband to do a lot of things” and another who echoed,
“I don’t mind asking for help, but I resent it”. From the
combination of dyspnea and fatigue, many women had
to dramatically change their lives, and for the active
women, this was perceived as a loss of identity: “…my
active lifestyle has just taken a back seat to just trying to
manage to get through the day”.
Embarrassment and guilt
Participants’ physical limitations or their inability to work
or their need to use supplemental oxygen (or these in
combination) made women feel embarrassed or guilty
about “appearing weak” and generally “bad [about] having
to say ‘let’s go slower’ because I don’t want to go slower”.
Defiance and resilience
Many comments demonstrated that women had moved
past the initial shock of being diagnosed with LAM
(“Initially [at the time of diagnosis] you go through all
these emotions, [and] now you might have an occasional
moment, but you don’t get stuck there anymore.”). Sev-
eral participants described how they had adapted in
many ways to life with LAM: physically (“we [she and
her husband] still go together and enjoy the things we
used to enjoy [going on bike rides], it’s just at a differentpace.”); and emotionally (“I decided to be in charge of it
[living with LAM]. I put myself back in charge again and
said ‘ok’”).
There was a sense of defiance to “just keep living with
this [LAM]” no matter what challenges the disease
brought; a commitment to “finding something you can
do that makes you happy and that you feel like you are
contributing”; and to “let go a little bit and let people
take care of me”. One participant who used supplemen-
tal oxygen described how she was committed to con-
tinuing to live her life on her terms, “[women who see
me at the gym say] ‘you are such an inspiration! You are
here with oxygen’…and I said, ‘I am not an inspiration. I
am just stubborn’”.
Discussion
We recruited 37 women with either TSC- or S-LAM to
participate in one of six FGs to gain an improved under-
standing of the symptoms and other effects of living
with the disease. This is the first such study of patients
with LAM. In a disease as rare as LAM, 37 is an impres-
sive number of subjects—one that we could have never
achieved without the willingness of the LAM community
to allow us to conduct our study at LAMposium.
Not surprisingly, exertional dyspnea was perceived as
a prominent symptom—it was present with activities
ranging from low-energy-demand-activities, like washing
hair, to high-energy-demand-activities, like walking up
inclines. In the National Heart Lung and Blood Insti-
tute’s (NHLBI) study of 203 women with LAM, dyspnea
was the most prominent symptom, present in over 70%
of subjects at baseline [7]. Wheezing was reported by
46% and cough by 31% of participants in that study. In
our cohort, we were impressed by the prominence of fa-
tigue, both in terms of how frequently it was mentioned
across FGs and how severely impairing it was for so
many women. We suspect fatigue was not asked about
specifically in the NHLBI study. We were also struck by
the perceived influence of weather on the severity of
shortness of breath and other chest symptoms in our FG
participants. Another symptom mentioned by several
women—but one that we have not had LAM patients
volunteer to us in clinic—was abdominal distension and
feeling bloated. None had chyloperitoneum or other
intra-abdominal abnormalities to account for this symp-
tom. The fact that each of the seven symptoms and five
psychological experiences was mentioned in more than
half (at least four) of the focus groups (and half the
topics were mentioned in all seven focus groups) sup-
ports the validity of these themes as capturing the per-
ceptions of LAM patients.
The paucity of published data makes placing the re-
sults of our study in the context of what is known about
the psychological effects of living with LAM difficult. In
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Summary of the SF-36 (a summary measure that in-
cludes items which ask about various aspects of mental
health including mood), were no different from norma-
tive values from the US adult general population [7].
However, questionnaires are unable to fully capture the
richness of data obtained from FGs. Among our partici-
pants, psychological effects were varied and hinged, at
least partially, on stage of illness. For most women, being
handed a diagnosis of a chronic, progressive disease was
devastating, placing women at risk for getting “stuck” in
an emotional valley. Once the dread of being diagnosed
had passed, women faced the daily frustrations of living
with LAM. This included dealing with symptoms and
being forced to adjust to LAM-imposed lifestyle modifi-
cations, including doing things at a slower pace, strat-
egizing and rationing energy to make it through the day.
These, and the other psychological experiences we ob-
served, including fear and worry, loss of identity, embar-
rassment and guilt are common to patients with other
chronic, debilitating lung diseases [14]. For example,
among patients with pulmonary hypertension (PH, an-
other disease that predominantly affects females), McDo-
nough and her colleagues identified two main themes to
describe the experience of living with PH—“holding back”
and “redefining life” [15]. Holding back included compo-
nents and subthemes like shortness of breath (the pre-
dominant symptom observed), fear of the effects of
physical overexertion, anticipation of disease progression,
and the inability to live with spontaneity; while “redefining
life” was driven by some being forced to use supplemental
oxygen, living with uncertainty and adapting to a new life-
style within the confines of PH.
Future research should focus on whether and how the
burdens of LAM can be lessened. For example, do LAM
patients derive benefits in functional capacity, symptom
severity and quality of life from traditional pulmonary
rehabilitation (PR) programs? We suspect they do, but
to our knowledge, this has not been systematically exam-
ined. Investigators could assess each component of PR
to develop new, or revise existing, practices to maximize
their benefit for LAM patients. It was abundantly clear
to us that LAM patients (and their families) enjoyed the
camaraderie and educational environment of LAMpo-
sium. More than that, LAMposium united, unified and
empowered LAM patients against the disease. Through
this meeting and several other efforts, the LAM Founda-
tion has become a model for patient advocacy, network-
ing and research for rare diseases.
As is common in qualitative research, this study is po-
tentially limited by its relatively small sample size. How-
ever, for a rare disease like LAM, 37 subjects is not a
trivial amount. Furthermore, like other qualitative stud-
ies, the goal here was to seek depth rather than breadth,and we believe we achieved our goal. It is possible that
the women who participated in these FGs are not repre-
sentative of others living with LAM. While we sought to
mitigate this possibility by conducting focus groups at
the LAMposium meeting, which draws a diverse group
of patients from across the nation, it is nonetheless diffi-
cult to determine generalizability to the larger LAM popu-
lation, including patients who were unable or unwilling to
travel. We do not have data on how many women actively
participated in support groups; one could reasonably ex-
pect that those who did could have a different emotional
experience of living with LAM. Reflecting the new land-
scape of LAM, the majority of participants were taking
sirolimus. This could have influenced experiences in mul-
tiple ways: drug side effects could be responsible for
certain physical symptoms and/or the hope that—for the
first time—having an effective therapy for LAM might
have positively affected emotional well-being. Finally, the
women with TSC may have been affected by non-LAM
aspects of their disease; given that our focus was on LAM
(and not other manifestations of TSC, like the dermato-
logical or neurological), we consciously chose not to iden-
tify those aspects or probe to discern their impact on the
TSC-LAM patients’ daily lives.
In summary, we conducted FGs with 37 women who
have either TSC- or S-LAM and captured a rich cache of
data on their physical and psychological experiences of liv-
ing with this disease. The most imposing symptoms were
shortness of breath and fatigue, and the psychological ex-
perience was dominated by frustration and worry. Add-
itional research is needed to determine whether and how
the burdens of this disease can be mitigated.
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